company background image
EOLS logo

Evolus NasdaqGM:EOLS Stock Report

Last Price

US$13.51

Market Cap

US$866.9m

7D

6.6%

1Y

36.5%

Updated

02 Dec, 2024

Data

Company Financials +

EOLS Stock Overview

A performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. More details

EOLS fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Evolus, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Evolus
Historical stock prices
Current Share PriceUS$13.51
52 Week HighUS$17.82
52 Week LowUS$9.38
Beta1.31
11 Month Change-19.34%
3 Month Change-13.29%
1 Year Change36.53%
33 Year Change145.64%
5 Year Change10.74%
Change since IPO17.48%

Recent News & Updates

Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26%

Nov 13
Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26%

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Oct 22
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus Continues To Make Progress

Aug 02

Recent updates

Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26%

Nov 13
Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26%

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Oct 22
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus Continues To Make Progress

Aug 02

Evolus, Inc. (NASDAQ:EOLS) Looks Just Right With A 32% Price Jump

Aug 02
Evolus, Inc. (NASDAQ:EOLS) Looks Just Right With A 32% Price Jump

Evolus (NASDAQ:EOLS) Is Making Moderate Use Of Debt

Jul 13
Evolus (NASDAQ:EOLS) Is Making Moderate Use Of Debt

Evolus: Chiseling Away At The Aesthetic Market

May 22

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

May 10
Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Mar 20

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 10
The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Jan 18
Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Jan 18
Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Jun 16
Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Nov 06
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Sep 21

Evolus: Turning That Frown Upside Down

Sep 11

Evolus appoints Experian's exec as CFO

Aug 30

Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Aug 04
Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Evolus Q2 2022 Earnings Preview

Aug 01

Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?

Mar 21
Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?

Shareholder Returns

EOLSUS PharmaceuticalsUS Market
7D6.6%1.9%0.7%
1Y36.5%12.1%32.2%

Return vs Industry: EOLS exceeded the US Pharmaceuticals industry which returned 12.4% over the past year.

Return vs Market: EOLS exceeded the US Market which returned 31.9% over the past year.

Price Volatility

Is EOLS's price volatile compared to industry and market?
EOLS volatility
EOLS Average Weekly Movement7.9%
Pharmaceuticals Industry Average Movement10.0%
Market Average Movement6.3%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Stable Share Price: EOLS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: EOLS's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012322David Moatazediwww.evolus.com

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names.

Evolus, Inc. Fundamentals Summary

How do Evolus's earnings and revenue compare to its market cap?
EOLS fundamental statistics
Market capUS$866.87m
Earnings (TTM)-US$55.46m
Revenue (TTM)US$248.33m

3.4x

P/S Ratio

-15.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EOLS income statement (TTM)
RevenueUS$248.33m
Cost of RevenueUS$74.64m
Gross ProfitUS$173.69m
Other ExpensesUS$229.15m
Earnings-US$55.46m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.88
Gross Margin69.94%
Net Profit Margin-22.33%
Debt/Equity Ratio2,057.9%

How did EOLS perform over the long term?

See historical performance and comparison